Zevra Therapeutics ZVRA Cash Flow Statement (2014-2026)

NASDAQ ZVRA
$12.40 -0.14 (-1.12%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Zevra Therapeutics Quarterly Cash Flow Statement

Periods 50 quarters
Latest Jun 2026

Zevra Therapeutics reported cash from operations of $17.03M and free cash flow of $16.82M for the quarter ended Jun 2026, up 573.0% year over year. This cash flow statement covers 50 quarters of results from Mar 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-1.76M-2.70M-1.86M-24.04M-6.62M5.75M-13.22M-2.57M-10.37M-19.89M-16.62M-19.93M-33.23M-35.74M-3.10M74.71M-0.54M12.16M37.89M8.75M
Share-based CompensationStock Comp.
5.49M0.82M5.49M6.89M0.91M0.95M8.27M8.27M8.27M23.91M9.93M9.93M9.93M4.02M3.12M2.46M2.77M4.28M3.10M2.97M
Gains from Investment SecuritiesGains Investment
-0.33M-0.07M-0.24M-0.03M-0.02M-0.03M0.00M
Asset Writedowns and ImpairmentWritedown
3.20M2.00M0.50M58.71M0.50M
Cash from OperationsCash from Ops.
-2.73M-0.85M-3.55M-4.10M-6.60M-4.46M-4.04M-8.70M-4.63M-16.16M-16.16M-19.11M-18.14M-16.25M-8.22M-3.60M4.71M5.52M6.14M17.03M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.89M0.30M0.76M1.21M0.86M0.62M0.59M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.07M0.06M0.07M0.18M0.40M0.30M0.08M0.08M0.06M0.79M1.56M1.56M1.62M1.65M1.65M1.65M0.39M0.36M0.37M0.32M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.27M-0.09M1.79M-0.50M3.35M2.13M-0.48M6.21M-4.11M7.45M-9.07M0.64M-1.16M2.72M2.11M4.86M-1.36M6.37M-6.89M5.74M
Change in InventoryChange Inventory
-0.04M-0.24M0.13M-0.05M-0.07M-0.07M-0.02M2.58M0.99M0.58M4.71M0.20M0.38M0.19M0.53M0.18M0.14M
Change in Account PayablesChange Payables
-4.39M-0.50M
Change in Accured ExpensesChange Accured Exp.
-0.19M0.78M-0.49M1.12M0.63M1.87M3.84M-0.89M2.45M5.73M-7.31M-1.30M-1.99M6.99M-7.26M-4.00M-4.73M0.41M-0.53M2.32M
Investing Activities
Capital ExpendituresCapex
0.00M0.02M0.02M0.01M0.03M-0.45M0.03M0.02M0.17M0.07M0.10M0.21M0.55M-0.03M0.04M0.22M
Sales of Property, Plant and EquipmentPP&E (Sale)
-0.14M0.04M
Change in IntangiblesChange Intangibless
43.94M5.00M
Acquisitions
30.40M
Change in Acquisitions & DivestmentsChange Acquisitions
0.30M9.50M15.62M14.79M10.01M0.20M18.00M12.50M60.50M87.50M93.97M49.25M
Cash from Investing ActivitiesCash from Investing
-0.00M-15.44M-3.85M-33.08M0.27M-0.06M-17.55M34.04M-44.46M10.59M14.79M-0.13M-31.35M-5.47M10.54M11.93M-4.58M0.23M79.62M31.45M
Financing Activities
Other financing activitiesOther financing
10.70M10.70M0.32M0.05M-0.00M1.15M0.16M0.79M1.98M0.97M3.01M2.68M9.17M
Cash from Financing ActivitiesCash from Financing
1.94M-2.87M-4.73M13.75M-0.41M-0.26M-3.75M0.95M26.26M5.00M1.22M15.33M64.77M0.80M1.61M1.38M6.53M2.55M-52.80M1.58M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.92M1.43M5.78M0.96M
Net Equity Issued and RepurchasedNet Equity Issued
6.11M1.22M-0.07M63.37M
Additional items
Exchange Rate EffectFX Effect
0.01M0.19M0.07M-0.27M-0.10M0.35M-0.04M0.32M-0.49M0.67M-0.37M0.66M0.06M-0.32M0.23M-0.34M
Change in Cash
-0.79M-19.16M-12.13M-23.43M-6.72M-4.59M-25.29M26.02M-22.93M-0.22M-0.20M-3.59M14.78M-20.25M3.56M10.37M6.73M7.97M33.19M49.73M
Free Cash FlowFCF
-2.73M-0.86M-3.57M-4.12M-6.63M-4.02M-4.07M-8.73M-4.80M-16.23M-16.16M-19.11M-18.14M-16.25M-8.32M-3.81M4.16M5.55M6.11M16.82M
Net Cash FlowNCF
-0.79M-19.16M-12.13M-23.43M-6.74M-4.78M-25.35M26.28M-22.82M-0.57M-0.15M-3.91M15.27M-20.93M3.93M9.71M6.66M8.29M32.96M50.07M